Latest Clinical News

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (03-28-2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (03-23-2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (03-22-2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also... Continue Reading

Dealing with Distress (03-17-2017)

Why it’s important to acknowledge distress during cancer care and what to do about it By Teresa L. Deshields and Clorinda Walley The moment a patient is diagnosed with cancer, one symptom is likely to surface: distress. Sadness, fear, helplessness,... Continue Reading

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (03-16-2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation (03-16-2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma (03-15-2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar... Continue Reading

Know Your Treatment Options: Colorectal Cancer Liver Metastases (03-13-2017)

Nearly 136,000 Americans are expected to be diagnosed with colorectal (CRC) cancer this year,1 and more than 50% will have their cancer spread to their liver.2  Many individuals with CRC involving the liver erroneously conclude that they have no treatment... Continue Reading

Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC (03-7-2017)

The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive... Continue Reading

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response? (03-6-2017)

A clinical study with Keytruda (pembrolizumab) in a novel untried combination is the first ovarian cancer clinical trial to incorporate gut flora analysis.  Dr. Emese Zsiros, the study’s Principal Investigator, explains a new, unique clinical trial... Continue Reading

Proton Beam Therapy may Improve Outcomes for Rectal Cancer (03-6-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions (03-3-2017)

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common cancer in women. The thyroid gland is a butterfly-shaped... Continue Reading

Next Page »